VIVUS Earnings: Here’s Why Investors are Not Excited Now

Google+ | + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

VIVUS Inc. (NASDAQ:VVUS) had a loss and beat Wall Street’s expectations, BUT came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 7%.

These stocks are hitting our Profit Targets. Click here now to discover winning stocks!

VIVUS Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased to $-0.12 in the quarter versus EPS of $-0.14 in the year-earlier quarter.

Actual vs. Wall St. Expectations: VIVUS Inc. reported adjusted EPS loss of $0.12 per share. By that measure, the company beat the mean analyst estimate of $-0.44. It missed the average revenue estimate of $3.09 million.

Quoting Management: “We believe in the long-term value of our franchise, and are focused on retaining and enhancing that value for our stockholders,” stated Leland Wilson, chief executive officer of VIVUS. “In 2012, we obtained FDA approval for QsymiaTM and STENDRATM and launched Qsymia in the U.S. Since approval, we have dedicated resources and been actively engaged in the process of educating physicians and creating awareness for Qsymia. In order to expand access to Qsymia, we submitted to FDA in mid-October 2012 a modification of the REMS that, pending approval, would allow patients to access Qsymia through select certified retail pharmacies. We continue to make substantial progress in obtaining reimbursement coverage. Our goals for 2013 include expanding both access and reimbursement for Qsymia as well as securing partnerships for STENDRA.”

Key Stats (on next page)…

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business